FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202202735> ?p ?o ?g. }

• W3202202735 abstract "Objective: We report interim findings from a study evaluating efficacy and safety of PTC-AADC, a recombinant adeno-associated virus vector containing human cDNA encoding AADC. Background: AADC deficiency is caused by mutations in the gene encoding the enzyme AADC, resulting in dopamine deficiency and movement disorders. Current treatments fail to restore dopamine levels and improve motor function. Design/Methods: This is a 2-year interim analysis from a 5-year, phase 1/2, prospective, open-label study in AADC deficiency using bilateral intraputaminal injections of 1.8 × 1011 vg PTC-AADC. Primary efficacy end point was proportion achieving key milestones using Peabody Developmental Motor Scale, Second Edition (PDMS-2) vs historical controls (n=82). Secondary end points included changes in PDMS-2, Alberta Infant Motor Scale (AIMS), and Bayley-III, and body weight. Pharmacodynamic end points included putaminal 18F-DOPA uptake on PET. Safety end points included treatment-emergent adverse events (TEAEs) and viral shedding. Mean follow-up was 39.9 months. Results: Of 10 patients treated, 1 withdrew at 11 months (influenza B encephalopathy leading to death). Others completed follow-up through year 2. Two years post-treatment, 50% of patients achieved full head control, 33% were able to sit unassisted, and 22% could stand with support. Mean PDMS-2 total score increased significantly from baseline at 24 months. Similar trends were seen with AIMS and Bayley-III total scores. Hypotonia, oculogyric crises, limb dystonia, and stimulus-provoked dystonia decreased. Mean putaminal 18F-DOPA uptake increased by year 1 through year 2. No viral shedding was detected. All patients experienced ≥1 TEAE (mostly mild or moderate); none were considered definitely treatment related. 27/131 TEAEs were possibly treatment related, including 18 dyskinesia episodes; most resolved within 6 months. Conclusions: Children with AADC deficiency achieved improvements in motor function after intraputaminal PTC-AADC therapy. No new safety signals were identified. These findings support the efficacy and safety of PTC-AADC in AADC deficiency. Disclosure: Hwu Wuh-Liang has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC therapeutics. The institution of Hwu Wuh-Liang has received research support from PTC therapeutics. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Avexis/Norvatis. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Yin-Hsiu Chien has received research support from Biogen. The institution of Yin-Hsiu Chien has received research support from Sanofi Genzyme. Ni-Chung Lee has nothing to disclose. Sheng-Hong Tseng has nothing to disclose. Mark Pykett has received personal compensation for serving as an employee of PTC Therapeutics. Mark Pykett has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for PTC Therapeutics. Mark Pykett has received stock or an ownership interest from PTC Therapeutics. Mark Pykett has received personal compensation in the range of $10,000-$49,999 for serving as a Observer with Pharming Group. The institution of Chun-Hwei Tai has received research support from National Taiwan University Hospital." @default.
• W3202202735 created "2021-10-11" @default.
• W3202202735 creator A5036816247 @default.
• W3202202735 creator A5037531175 @default.
• W3202202735 creator A5044118624 @default.
• W3202202735 creator A5046826963 @default.
• W3202202735 creator A5064022308 @default.
• W3202202735 creator A5076752267 @default.
• W3202202735 date "2021-04-13" @default.
• W3202202735 modified "2023-09-24" @default.
• W3202202735 title "Improved Motor Function in Children With Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Treated With Eladocagene Exuparvovec (PTC-AADC): Interim Findings From a Phase 1/2 Study (2057)" @default.
• W3202202735 hasPublicationYear "2021" @default.
• W3202202735 type Work @default.
• W3202202735 sameAs 3202202735 @default.
• W3202202735 citedByCount "0" @default.
• W3202202735 crossrefType "journal-article" @default.
• W3202202735 hasAuthorship W3202202735A5036816247 @default.
• W3202202735 hasAuthorship W3202202735A5037531175 @default.
• W3202202735 hasAuthorship W3202202735A5044118624 @default.
• W3202202735 hasAuthorship W3202202735A5046826963 @default.
• W3202202735 hasAuthorship W3202202735A5064022308 @default.
• W3202202735 hasAuthorship W3202202735A5076752267 @default.
• W3202202735 hasConcept C118552586 @default.
• W3202202735 hasConcept C126322002 @default.
• W3202202735 hasConcept C134018914 @default.
• W3202202735 hasConcept C187212893 @default.
• W3202202735 hasConcept C197934379 @default.
• W3202202735 hasConcept C2778559928 @default.
• W3202202735 hasConcept C513476851 @default.
• W3202202735 hasConcept C535046627 @default.
• W3202202735 hasConcept C58824617 @default.
• W3202202735 hasConcept C61943457 @default.
• W3202202735 hasConcept C71924100 @default.
• W3202202735 hasConceptScore W3202202735C118552586 @default.
• W3202202735 hasConceptScore W3202202735C126322002 @default.
• W3202202735 hasConceptScore W3202202735C134018914 @default.
• W3202202735 hasConceptScore W3202202735C187212893 @default.
• W3202202735 hasConceptScore W3202202735C197934379 @default.
• W3202202735 hasConceptScore W3202202735C2778559928 @default.
• W3202202735 hasConceptScore W3202202735C513476851 @default.
• W3202202735 hasConceptScore W3202202735C535046627 @default.
• W3202202735 hasConceptScore W3202202735C58824617 @default.
• W3202202735 hasConceptScore W3202202735C61943457 @default.
• W3202202735 hasConceptScore W3202202735C71924100 @default.
• W3202202735 hasLocation W32022027351 @default.
• W3202202735 hasOpenAccess W3202202735 @default.
• W3202202735 hasPrimaryLocation W32022027351 @default.
• W3202202735 hasRelatedWork W2518213089 @default.
• W3202202735 hasRelatedWork W2790507197 @default.
• W3202202735 hasRelatedWork W2800417626 @default.
• W3202202735 hasRelatedWork W2800528626 @default.
• W3202202735 hasRelatedWork W2801706337 @default.
• W3202202735 hasRelatedWork W2803651213 @default.
• W3202202735 hasRelatedWork W2804412694 @default.
• W3202202735 hasRelatedWork W2806319173 @default.
• W3202202735 hasRelatedWork W2811297374 @default.
• W3202202735 hasRelatedWork W2884571446 @default.
• W3202202735 hasRelatedWork W2885049414 @default.
• W3202202735 hasRelatedWork W3153604484 @default.
• W3202202735 hasRelatedWork W3156802418 @default.
• W3202202735 hasRelatedWork W3161104252 @default.
• W3202202735 hasRelatedWork W3183081226 @default.
• W3202202735 hasRelatedWork W3198538026 @default.
• W3202202735 hasRelatedWork W3199451569 @default.
• W3202202735 hasRelatedWork W3202067723 @default.
• W3202202735 hasRelatedWork W3207625114 @default.
• W3202202735 hasRelatedWork W3091630617 @default.
• W3202202735 hasVolume "96" @default.
• W3202202735 isParatext "false" @default.
• W3202202735 isRetracted "false" @default.
• W3202202735 magId "3202202735" @default.
• W3202202735 workType "article" @default.